5F-CUMYL-PINACA (also known as SGT-25 and sometimes sold in e-cigarette form as C-Liquid) is an indazole-3-carboxamide based synthetic cannabinoid. 5F-CUMYL-PINACA acts as a potent agonist for the cannabinoid receptors, with the original patent claiming approximately 4x selectivity for CB<sub>1</sub>, having an EC<sub>50</sub> of <0.1 nM for human CB<sub>1</sub> receptors and 0.37 nM for human CB<sub>2</sub> receptors. In more recent assays using different techniques, 5F-CUMYL-PINACA was variously found to have an EC<sub>50</sub> of 0.43 nM at CB<sub>1</sub> and 11.3 nM at CB<sub>2</sub>, suggesting a somewhat higher CB<sub>1</sub> selectivity of 26 times, or alternatively 15.1 nM at CB<sub>1</sub> and 34.8 nM at CB<sub>2</sub> with only 2.3 times selectivity, however these figures cannot be directly compared due to the different assay techniques used in each case.
In the United States, 5F-CUMYL-PINACA was temporarily emergency scheduled by the DEA in 2019. and made a permanent Schedule I Controlled Substance on April 7, 2022. Sweden's public health agency suggested classifying 5F-CUMYL-PINACA as a hazardous substance on November 10, 2014.